GlassScriptPhysician profile
Jennifer Tomlin
NPI 1891306452
$1,530.62
in general payments reported to CMS, 2019-2025
22 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $321 · 2023: $311 · 2024: $213 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $324.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.95 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $168.09 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $128.17 | 2022-2025 | |
| Insulet Corporation | $78.26 | 2023-2025 | Omnipod, Omnipod |
| Janssen Pharmaceuticals, INC | $75.71 | 2021 | |
| Lilly USA, LLC | $64.50 | 2025 | Kisunla |
| Biohaven Pharmaceuticals, INC. | $47.70 | 2021 | |
| Novo Nordisk INC | $40.12 | 2022 | |
| Pfizer INC. | $39.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $32.38 | 2021-2025 | Gardasil 9, Capvaxive |
| Neurocrine Biosciences, INC. | $32.33 | 2022 | |
| Exact Sciences Corporation | $28.26 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ucb, INC. | $23.92 | 2023 | Briviact |
| Xeris Pharmaceuticals, INC. | $21.40 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.69 | 2021 | |
| Amarin Pharma, INC. | $16.68 | 2021 | |
| Gilead Sciences, INC. | $16.64 | 2023 | |
| Sumitomo Pharma America, INC. | $14.51 | 2023 | Gemtesa |
| Alkermes, INC. | $14.34 | 2025 | Aristada, Aristada Initio |
| Sanofi Pasteur INC. | $13.86 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tomlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.